U.S. Markets open in 2 hrs 42 mins

Novartis and Peers in February 2018: Analyst Recommendations

Margaret Patrick
Novartis and Peers in February 2018: Analyst Recommendations

For 4Q17, Novartis (NVS) reported revenues of ~$12.9 billion, which represents a YoY (year-over-year) rise of 5% on a reported basis and a rise of 2% on a CC (constant currency) basis. Although the rising sales volumes of the recently launched Entresto and Cosentyx contributed around 7 percentage points to the company’s 4Q17 revenue performance, this gain was offset by 3 percentage points due to generic erosion and by 2 percentage points due to increased pricing pressures. Novartis reported an operating income of around $2.1 billion, which represents a YoY rise of 42% on a reported basis and a rise of 41% on a CC basis, despite the significant generic competition its major drugs are facing.